Your browser doesn't support javascript.
loading
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Overton, Edgar T; Richmond, Gary; Rizzardini, Giuliano; Thalme, Anders; Girard, Pierre-Marie; Wong, Alexander; Porteiro, Norma; Swindells, Susan; Reynes, Jacques; Noe, Sebastian; Harrington, Conn; Español, Carlos Martín; Acuipil, Carolina; Aksar, Asma; Wang, Yuanyuan; Ford, Susan L; Crauwels, Herta; van Eygen, Veerle; Van Solingen-Ristea, Rodica; Latham, Christine L; Thiagarajah, Shanker; D'Amico, Ronald; Smith, Kimberly Y; Vandermeulen, Kati; Spreen, William R.
Afiliación
  • Overton ET; Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Richmond G; Department of Medicine, Broward Health Medical Center, Fort Lauderdale, Florida, USA.
  • Rizzardini G; Department of Infectious Diseases, Fatebenefratelli Sacco Hospital, Milan, Italy.
  • Thalme A; School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Girard PM; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Wong A; Department of Infectious and Tropical Diseases and Inserm, University of Paris, St-Antoine Hospital, Paris, France.
  • Porteiro N; Department of Medicine, University of Saskatchewan, Regina, Canada.
  • Swindells S; Fundación IDEAA, Buenos Aires, Argentina.
  • Reynes J; Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Noe S; Department of Infectious Diseases, Montpellier University Hospital, Montpellier, France.
  • Harrington C; Inserm, University of Montpellier, Montpellier, France.
  • Español CM; HIV Research and Clinical Care Center, MVZ München Am Goetheplatz, Munich, Germany.
  • Acuipil C; Clinical Development, ViiV Healthcare, Durham, North Carolina, USA.
  • Aksar A; GlaxoSmithKline, Brentford, United Kingdom.
  • Wang Y; Research and Development, ViiV Healthcare, Durham, North Carolina, USA.
  • Ford SL; GlaxoSmithKline, Manchester, United Kingdom.
  • Crauwels H; Development Biostatistics, GlaxoSmithKline, Collegeville, Pennsylvania, USA.
  • van Eygen V; Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Durham, North Carolina, USA.
  • Van Solingen-Ristea R; Clinical Pharmacology, Janssen Research and Development, Beerse, Belgium.
  • Latham CL; Clinical Microbiology and Immunology, Janssen Research and Development, Beerse, Belgium.
  • Thiagarajah S; Medical Department, Janssen Research and Development, Beerse, Belgium.
  • D'Amico R; Translational Medicine Research, ViiV Healthcare, Durham, North Carolina, USA.
  • Smith KY; Pharma Safety, GlaxoSmithKline, Brentford, United Kingdom.
  • Vandermeulen K; Research and Development, ViiV Healthcare, Durham, North Carolina, USA.
  • Spreen WR; Research and Development, ViiV Healthcare, Durham, North Carolina, USA.
Clin Infect Dis ; 76(9): 1646-1654, 2023 05 03.
Article en En | MEDLINE | ID: mdl-36660819
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Seropositividad para VIH / Fármacos Anti-VIH Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Seropositividad para VIH / Fármacos Anti-VIH Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos